Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Michael A PostowDebra A GoldmanAlexander N ShoushtariAllison Betof WarnerMargaret K CallahanParisa MomtazJames W SmithyEllesa NaitoMarina K CugliariVladislav RaberOmar EtonSuresh G NairKatherine S PanageasJedd D WolchokPaul B ChapmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The efficacy and toxicity of standard four dose nivo + ipi induction therapy in melanoma is likely driven by the first two doses. An interim computed tomography scan after two doses guided cessation of combination dosing and identified almost all responders. Longer follow-up and further study are needed to fully understand the implications of a shortened induction course of nivo + ipi.